You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 7,122,183

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,122,183

Title:	Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
Abstract:	The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF.alpha. inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF.alpha. inhibitors.
Inventor(s):	Mohler; Kendall M. (Seattle, WA), Barone; Dauphine S. (Seattle, WA), Peschon; Jacques J. (Seattle, WA), Kennedy; Mary K. (Seattle, WA), Pluenneke; John D. (Seattle, WA)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	10/648,136
Patent Claims:	1. A method of treating an psoriatic arthritis, arthritis nodosa, seronegative spondylarthropathies, or inflammatory bowel diseases in a patient, said method comprising administering to the patient an antibody specific for CD30L that is capable of inhibiting the binding of CD30 to CD30L, wherein the antibody is administered according to a regimen of dose and frequency of administration that is adequate to induce a sustained improvement in at least one indicator that reflects the severity of the patient's condition, the improvement being considered sustained if the patient exhibits the improvement on at least two occasions separated by at least one day. 2. The method according to claim 1, wherein the patient is a human. 3. The method according to claim 2, wherein the seronegative spondylarthropathies is ankylosing spondylitis. 4. The method according to claim 2, wherein the spondylarthropathies is treated. 5. The method according to claim 2, wherein the inflammatory bowel diseases is selected from the group consisting of Crohn's disease and ulcerative colitis. 6. The method according to claim 2, wherein the antibody is administered concurrently with a second agent that is an antagonist of TNF.alpha.. 7. The method according to claim 6, wherein the second agent is an antagonist of TNF.alpha. selected from the group consisting of etanercept, p55 TNFR-Ig fusion protein and an antibody against TNF.alpha.. 8. The method according to claim 7, wherein the antagonist of TNF.alpha. is an antibody against TNF.alpha., and further wherein said antibody is selected from the group consisting of infliximab, D2E7 and CDP571. 9. The method according to claim 2, wherein the antibody specific for CD30L is a monoclonal antibody. 10. The method according to claim 9, wherein the antibody specific for CD30L is a humanized antibody. 11. The method according to claim 9, wherein the antibody specific for CD30L is a human antibody. 12. The method according to claim 3, wherein the antibody specific for CD30L is a monoclonal antibody. 13. The method according to claim 12, wherein the antibody specific for CD30L is a humanized antibody. 14. The method according to claim 12, wherein the antibody specific for CD30L is a human antibody. 15. The method according to claim 4, wherein the antibody specific for CD30L is a monoclonal antibody. 16. The method according to claim 15, wherein the antibody specific for CD30L is a humanized antibody. 17. The method according to claim 15, wherein the antibody specific for CD30L is a human antibody. 18. The method according to claim 5, wherein the antibody specific for CD30L is a monoclonal antibody. 19. The method according to claim 18, wherein the antibody specific for CD30L is a humanized antibody. 20. The method according to claim 18, wherein the antibody specific for CD30L is a human antibody. 21. The method according to claim 6, wherein the antibody specific for CD30L is a monoclonal antibody. 22. The method according to claim 21, wherein the antibody specific for CD30L is a humanized antibody. 23. The method according to claim 21, wherein the antibody specific for CD30L is a human antibody.

Details for Patent 7,122,183

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2020-08-08
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2020-08-08
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2020-08-08
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2020-08-08
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2020-08-08
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2020-08-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.